Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single‐center report

BACKGROUND: Emicizumab, a bispecific antibody factor VIII mimetic, is approved for prophylaxis in hemophilia, and has different risks and side effects compared to factor VIII products. OBJECTIVE: To better understand the early impact of emicizumab on our patients at the University of Colorado Hemoph...

Descripción completa

Detalles Bibliográficos
Autores principales: Warren, Beth Boulden, Chan, Adrian, Manco‐Johnson, Marilyn, Branchford, Brian R., Buckner, Tyler W., Moyer, Genevieve, Gibson, Elizabeth, Thornhill, Dianne, Wang, Michael, Ng, Christopher J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331949/
https://www.ncbi.nlm.nih.gov/pubmed/34377887
http://dx.doi.org/10.1002/rth2.12571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331949/
https://www.ncbi.nlm.nih.gov/pubmed/34377887
http://dx.doi.org/10.1002/rth2.12571

Ejemplares similares